KAN 002
Alternative Names: KAN-002Latest Information Update: 26 Sep 2024
Price :
$50 *
At a glance
- Originator Kanvas Biosciences
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 04 Sep 2024 KAN 002 is available for licensing as of 04 Sep 2024. https://www.kanvasbio.com/ (Kanvas Biosciences pipeline, September 2024)
- 04 Sep 2024 Phase-I clinical trials in Inflammatory bowel diseases (unspecified route) prior to September 2024 (Kanvas Biosciences pipeline, September 2024)